Is MPT a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Medical Properties Trust (MPT) rests on Tenant re-tenanting and rent recovery: MPT spent 2024 and 2025 replacing bankrupt Steward with new operators and is guiding toward more than $1 billion in annualized cash rent by year-end 2026. Revenue (TTM) is ~$1.0 billion. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: MPT carries roughly $9.8 billion of debt against a market cap near $2.7 billion, so financial leverage magnifies both gains and losses and refinancing risk is real given maturities in 2026 and 2027. Whether MPT is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Medical Properties Trust, Inc. trades on the New York Stock Exchange under the ticker MPT and is one of the largest owners of hospital real estate in the world. Its model is sale-leaseback: it buys hospital buildings from operators, then leases the property back under long-term net leases where the tenant covers taxes, insurance, and maintenance. The portfolio spans general acute care hospitals, behavioral health facilities, and post-acute sites across the United States and Europe, and revenue comes almost entirely from contractual rent plus interest on loans MPT has made to some of its tenants. The investment picture is defined by a collapse from its former blue-chip status. After the 2024 bankruptcy of its largest tenant, Steward Health Care, MPT cut its dividend sharply, sold assets, and re-tenanted properties, and the stock fell from the mid-teens to around $4.85 with a roughly $2.7 billion market cap by mid-2026. Q1 2026 showed a return to net profit and normalized funds from operations of about $0.14 per share, but the results leaned on one-time items, tenant concentration remains high, and roughly $9.8 billion of debt hangs over the equity. It is a turnaround-and-deleveraging story, not a stable income staple.
What's the case for buying MPT?
1. Tenant re-tenanting and rent recovery
MPT spent 2024 and 2025 replacing bankrupt Steward with new operators and is guiding toward more than $1 billion in annualized cash rent by year-end 2026. The thesis rests on those replacement tenants actually paying contractual rent on schedule, which would restore cash flow and support the dividend. Any slippage in cash collection directly hits funds from operations.
2. Deleveraging and refinancing runway
With roughly $9.8 billion of debt and maturities stacked through 2026 and 2027, MPT has been raising secured financing and selling assets to push out its maturity wall. Management says it has addressed near-term maturities, and each successful refinancing or asset sale reduces the risk that debt costs swamp rental income. Progress here is the single biggest lever on the equity value.
3. Deep-value and high-yield setup
The stock carries a dividend yield near 7.5 percent and trades at a mid-single-digit multiple of normalized funds from operations, well below larger healthcare REITs. For investors who believe the tenant base stabilizes, that gap is the potential re-rating. It is also one of the most heavily shorted REITs, so any confirmation of stability can move the price sharply.
4. European and behavioral health diversification
MPT holds meaningful hospital assets in the United Kingdom, Germany, and other European markets, which diversifies away from any single United States operator or reimbursement regime. A one-time United Kingdom deferred tax benefit boosted Q1 2026 results, and the behavioral health and international portfolios provide rent streams that are somewhat decoupled from the troubled United States acute care tenants.
What are the risks to MPT?
MPT carries roughly $9.8 billion of debt against a market cap near $2.7 billion, so financial leverage magnifies both gains and losses and refinancing risk is real given maturities in 2026 and 2027. Tenant concentration is a recurring problem: the 2024 Steward bankruptcy forced a dividend cut and asset sales, and in March 2026 MPT declared defaults on properties leased to Healthcare Systems of America, its third-largest tenant at about 8 percent of assets, sending the stock down about 8 percent in a day. That March 2026 disclosure triggered securities-fraud investigations by several plaintiff law firms, and MPT has faced securities litigation before tied to its 2019 to 2023 disclosures, so legal and disclosure risk is an ongoing overhang. Hospital operators face reimbursement pressure, staffing shortages, and impairments, and MPT's Q1 2026 profit relied partly on one-time tax and cash-rent items rather than durable run-rate earnings. Walnut is not an investment adviser, and these factors make MPT materially more speculative than a typical healthcare REIT.
How is MPT valued? (as of JULY 2026)
Snapshot for MPT as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$1.0 billion
- Market cap: ~$2.7 billion
- Stock price: ~$4.85
- Dividend yield: ~7.5% (~$0.36/yr)
- Normalized FFO: ~$0.14/share (Q1 2026)
- Total debt: ~$9.8 billion
MPT trades at a mid-single-digit multiple of normalized funds from operations, a steep discount to larger healthcare REITs like Welltower and Ventas, which reflects its leverage and tenant risk rather than a bargain hiding in plain sight. Q1 2026 returned to net profit with about $252 million in quarterly revenue, but results were flattered by a one-time United Kingdom deferred tax benefit and cash-rent catch-ups. The valuation is a classic high-yield, high-risk setup where the discount and the danger are two sides of the same coin.
How do you decide if MPT is a buy?
Rather than asking whether MPT is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold MPT indirectly through an index or sector ETF before adding more.
For the full picture, see the MPT stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about MPT against your real portfolio and see your actual exposure before deciding.
The bottom line on MPT
The bottom line: Medical Properties Trust's story right now is Tenant re-tenanting and rent recovery, with revenue (ttm) at ~$1.0 billion. If you believe that narrative continues, the call is about sizing MPT sensibly and checking overlap with what you own; if you doubt it (the risk: mPT carries roughly $9.8 billion of debt against a market cap near $2.7 billion, so financial leverage magnifies both gains and losses and refinancing risk is real given maturities in 2026 and 2027.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
More on MPT
- MPT stock guide (what the company does, ETFs that hold it, similar stocks, and the themes it fits)
- MPT stock forecast (the drivers and risks shaping the outlook)
- Does MPT pay a dividend?
Build a basket around MPT with Walnut
Use Medical Properties Trust as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is MPT a good stock to buy right now?
+
The case for Medical Properties Trust right now is Tenant re-tenanting and rent recovery, with revenue (ttm) at ~$1.0 billion. If you believe that thesis holds, MPT is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is mPT carries roughly $9.8 billion of debt against a market cap near $2.7 billion, so financial leverage magnifies both gains and losses and refinancing risk is real given maturities in 2026 and 2027. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Medical Properties Trust do?
+
Medical Properties Trust, Inc.
What are the main risks of MPT?
+
MPT carries roughly $9.8 billion of debt against a market cap near $2.7 billion, so financial leverage magnifies both gains and losses and refinancing risk is real given maturities in 2026 and 2027. Tenant concentration is a recurring problem: the 2024 Steward bankruptcy forced a dividend cut and asset sales, and in March 2026 MPT declared defaults on properties leased to Healthcare Systems of America, its third-largest tenant at about 8 percent of assets, sending the stock down about 8 percent in a day. That March 2026 disclosure triggered securities-fraud investigations by several plaintiff law firms, and MPT has faced securities litigation before tied to its 2019 to 2023 disclosures, so legal and disclosure risk is an ongoing overhang. Hospital operators face reimbursement pressure, staffing shortages, and impairments, and MPT's Q1 2026 profit relied partly on one-time tax and cash-rent items rather than durable run-rate earnings. Walnut is not an investment adviser, and these factors make MPT materially more speculative than a typical healthcare REIT.
What does Medical Properties Trust do?
+
MPT is a real estate investment trust that owns hospital buildings and leases them back to healthcare operators under long-term net leases. It is one of the largest hospital landlords globally, with acute care, behavioral health, and specialty facilities across the United States and Europe. Its income is almost entirely contractual rent plus interest on tenant loans.
Why has MPT stock fallen so much?
+
The stock collapsed from the mid-teens after its largest tenant, Steward Health Care, went bankrupt in 2024, forcing a sharp dividend cut, asset sales, and re-tenanting. Heavy debt, roughly $9.8 billion, and repeated tenant troubles kept pressure on the shares, which traded near $4.85 by mid-2026. It is one of the most heavily shorted REITs.
Is MPT facing a securities-fraud lawsuit?
+
MPT faced securities litigation tied to its 2019 to 2023 disclosures, and after a March 2026 statement about defaults by tenant Healthcare Systems of America, several plaintiff law firms announced new securities-fraud investigations. These are ongoing legal overhangs that investors weigh, though the tenant and leverage stresses driving them are ordinary business risks for a hospital REIT under strain.
What is MPT's dividend yield?
+
As of July 2026, MPT pays about $0.09 per quarter, or roughly $0.36 annually, for a yield near 7.5 percent at a stock price around $4.85. The dividend was cut sharply from prior levels during the Steward crisis, and its durability depends on replacement tenants paying rent and on the company managing its debt maturities.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell MPT; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.